Trial Evaluating Cardiovascular Outcomes With Sitagliptin
TECOS celebrates enrolment milestone at the ADA
We are delighted to announce that more than 14,000 patients have now been recruited to the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) trial.
Investigators from across the globe joined the TECOS management team to celebrate reaching this milestone at the American Diabetes Association (ADA) conference in Philadelphia, USA on Saturday 9th June....
TECOS trial members gather for annual European meeting
On 22nd March, the Oxford-based TECOS team hosted a European Investigators Meeting for a selection of European sites in Noordwijkerhout, Netherlands - a region known fondly as the "Dune and Bulb Region".
Representatives from many of our new European sites were also there, and along with those from numerous existing sites, got the opportunity to learn about the trial and share experiences....